HBM HOLDINGS-B (02142.HK): Bispecific Antibody HBM7575 Approved for Clinical Trial by NMPA
NewTimeSpace: HBM Holdings Limited (02142.HK) announced that the Investigational New Drug (IND) application for HBM7575 (also known as SKB575), a long‑acting bispecific antibody targeting TSLP and an undisclosed target for the treatment of atopic dermatitis, has been approved by the National Medical Products Administration (NMPA) of China.
NewTimeSpace News: HBM Holdings Limited (02142.HK) issued a voluntary announcement on March 9, 2026, stating that the IND application for its self‑developed bispecific antibody HBM7575 has been approved by the NMPA for the treatment of atopic dermatitis.
HBM7575 (SKB575) is a long‑acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed target. The drug features a dual mechanism of action: on the one hand, it blocks the interaction between TSLP and its receptor, thereby inhibiting TSLP‑mediated signaling pathways and the activation of Th2 immune cells; on the other hand, binding and blocking of the additional undisclosed target provides a synergistic effect and overcomes drug resistance associated with single‑target TSLP antibodies.
Engineered for extended half‑life and favorable developability, the antibody enables subcutaneous administration. Based on preclinical half‑life data, the human half‑life is expected to support a dosing interval of more than three months, demonstrating best‑in‑class potential.
Pursuant to the collaboration agreement between the Company and Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (06990.HK, “Kelun-Biotech”), Kelun‑Biotech leads the design, global development and commercialization of HBM7575. HBM Holdings participates in the project’s investment and development, and will share benefits in accordance with the agreement.
The Company cautions that there can be no guarantee that the drug will be successfully developed or eventually commercialized. Shareholders and potential investors should exercise caution when dealing in the Company’s shares.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
